The first subject has been dosed in the Phase II clinical trial of its innovative small nucleic acid drug EDP167.
February 12, 2026
Source: drugdu
29
On February 9, Yiteng Jiahe (06998) issued an announcement, announcing that its innovative small nucleic acid drug...The first subject was successfully dosed in the Phase II clinical trial of EDP167.
This trial is aimed at adult patients with homozygous familial hypercholesterolemia (HoFH) and aims to evaluate the efficacy and safety of EDP167 in HoFH patients. The primary endpoint is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline 24 weeks after the first dose. The evaluation of the primary endpoint is expected to be completed in the fourth quarter of 2026.
EDP167 is an innovative siRNA therapy specifically designed to treat dyslipidemia. Its mechanism of action is independent of the LDL receptor pathway, overcoming the limitations of traditional lipid-lowering drugs. Prior to initiating a Phase II clinical trial for HoFH patients, the company completed a Phase I clinical study in healthy individuals and those with mild dyslipidemia. Results showed that EDP167 exhibited good safety and tolerability characteristics, and related data will be disclosed at a medical conference in 2026.
https://finance.eastmoney.com/a/202602093645079878.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- The first patient in the Phase IB/II trial of Verizon’s triple-negative breast cancer was successfully treated. February 12, 2026
- Watson Bio’s live attenuated varicella vaccine clinical trial approved February 12, 2026
- Novo Nordisk’s oral weight-loss drug advertisement has been flagged by the FDA for allegedly misleading advertising. February 12, 2026
- Visipine®, the first and only oral S1P receptor modulator for ulcerative colitis in my country, has been approved, ushering in a new era of “deep healing”. February 12, 2026
- Multi-dimensional Breakthroughs in Policy, Rules, and Pricing February 12, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
